Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Excellence Forum

Gastrointestinal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Thierry Andre, MD, St Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer
02/04/2025
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes...
02/04/2025
Oncology
Scott Kopetz, MD
Videos
Impact of Encorafenib Approval for BRAF V600E Mutant Colorectal Cancer
01/30/2025
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses...
01/30/2025
Oncology
Xuefeng Leng, MD, PhD, Sichuan Cancer Hospital & Institute
Videos
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma
01/28/2025
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains...
01/28/2025
Oncology
Anna Martling, MD, Karolinska Institutet
Videos
Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute
Videos
Treatment Patterns for Hepatocellular Carcinoma
12/18/2024
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP,...
12/18/2024
Oncology
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
Filippo Pietrantonio, MD
Videos
Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer
09/14/2024
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD,...
09/14/2024
Oncology
Jennifer Eads, MD, Abramson Cancer Center
Videos
Perioperative Chemotherapy Improved Survival Among Patients With Esophageal Adenocarcinoma
06/20/2024
Jennifer Eads, MD
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on...
06/20/2024
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology

Section Editor

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center, New York

Resources

Thierry Andre, MD, St Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer
02/04/2025
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes...
02/04/2025
Oncology
Scott Kopetz, MD
Videos
Impact of Encorafenib Approval for BRAF V600E Mutant Colorectal Cancer
01/30/2025
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses...
01/30/2025
Oncology
Xuefeng Leng, MD, PhD, Sichuan Cancer Hospital & Institute
Videos
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma
01/28/2025
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains...
01/28/2025
Oncology
Anna Martling, MD, Karolinska Institutet
Videos
Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute
Videos
Treatment Patterns for Hepatocellular Carcinoma
12/18/2024
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP,...
12/18/2024
Oncology
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
Filippo Pietrantonio, MD
Videos
Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer
09/14/2024
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD,...
09/14/2024
Oncology
Jennifer Eads, MD, Abramson Cancer Center
Videos
Perioperative Chemotherapy Improved Survival Among Patients With Esophageal Adenocarcinoma
06/20/2024
Jennifer Eads, MD
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on...
06/20/2024
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
FDA Approval
FDA Approves Mirdametinib for Patients With NF1-Associated Symptomatic, Inoperable Plexiform Neurofibromas
02/11/2025
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase...
02/11/2025
Oncology
Anna-Dorothea Wagner, MD
Conference Coverage
Response and Survival Outcomes With Trastuzumab Plus Chemotherapy for HER2-Positive Gastric Cancers
02/11/2025
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD,...
02/11/2025
Oncology
Marwan Fakih, MD
Conference Coverage
Optimal Botensilimab and Balstilimab Dose for Refractory Microsatellite Stable Colorectal Cancer
02/11/2025
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses...
02/11/2025
Oncology
News
Outcomes for Patients With Central Nervous System Tumors Harboring NTRK Gene Fusions
02/11/2025
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology
News
Risk of Thyroid Cancer and Glucagon-Like Peptide 1 Receptor Agonists
02/11/2025
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of...
02/11/2025
Oncology
Quiz
Lurbinectedin for Patients With Platinum-Sensitive Small Cell Lung Cancer
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Superior Efficacy Compared With Idecabtagene Vicleucel for Treatment of Triple-Class-Exposed R/R MM
02/10/2025
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel...
02/10/2025
Oncology
Matthew Davids, MD, MMSc
Videos
Strategies for Approaching BTK Inhibitor Resistance and Mutations Among Patients With Chronic Lymphocytic Leukemia
02/09/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia &...
02/09/2025
Oncology
KOL Roundtable
Videos
New Myelofibrosis Therapies and Potential Future Treatment Strategies
02/08/2025
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert...
02/08/2025
Oncology
Videos
Exploring Approaches and Strategies for Treating Patients With Relapsed/Refractory Myelofibrosis
02/08/2025
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert...
02/08/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use